Horizon Therapeutics' Daxdilimab Trial Falls Short on Primary Endpoint
- July 23rd, 2023
- 249 views
Horizon Therapeutics plc (Nasdaq: HZNP) reported disappointing results from its Phase 2 clinical trial for daxdilimab in the treatment of systemic lupus erythematosus (SLE), the most common type of lupus. The trial did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which measured low SLE disease activity.
However, the company reported numerical differences in other endpoints and stated that there were no safety concerns. Horizon Therapeutics remains committed to assessing the full dataset. The company's daxdilimab trials in alopecia areata, discoid lupus erythematosus, and lupus nephritis are still ongoing.
Following the announcement, $HZNP declined by $1.18 (-1.17%) to $100.00 in after-hours trading on Friday.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login